IView-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA

See more here


Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
– Fast Track-Designated Program Commencing Phase 2/3 Study in Q1 2019 –¬†

See more here


Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
Findings on Effect of REL-1017 on BDNF Plasma Levels Presented at Annual Meeting of the American College of Neuropsychopharmacology 

See more here


CEO of Group K Diagnostics Nominated to the Philadelphia Startup Leaders Board

See more here


Pillo Health Launches Innovative Home Health Assistant to Dispense Medication, Track Adherence, Deliver Care Plans

See more here


Group K Diagnostics Has Begun Part II of its Liver Function Clinical Trial

See more here


Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita

See more here